Recent Quotes
My Watchlist
Indicators
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tonix Pharmaceuticals Holding Corp. - Common Stock (NQ:TNXP)

9.230 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 960
Open 9.230
Bid (Size) 9.200 (500)
Ask (Size) 9.400 (2,700)
Prev. Close 9.230
Today's Range 9.230 - 9.230
52wk Range 9.190 - 25.50
Shares Outstanding 11,776,542
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Expands TONMYA(R) Medicare Coverage to 32 Million Lives
Via Investor Brand Network
News headline image
Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears ↗
Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Seth Lederman told attendees at the Cantor Healthcare Conference that the company’s near-term focus is the commercial launch of TONMYA, its FDA-approved... 
Via MarketBeat

Performance

YTD
-44.2%
-44.2%
1 Month
-34.0%
-34.0%
3 Month
-25.2%
-25.2%
6 Month
-33.6%
-33.6%
1 Year
-61.5%
-61.5%

More News

Read More
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Promotes Thomas Englese to Chief Commercial Officer
Via Investor Brand Network
NetworkNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Participate in Cantor 2026 Global Healthcare Conference
Via Investor Brand Network
Tonix Pharmaceuticals (NASDAQ:TNXP) Beats Revenue Estimates in First Full Quarter of TONMYA Sales ↗
Via Chartmill
News headline image
Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline ↗
Via MarketBeat
News headline image
Tonix Pharmaceuticals (TNXP) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Tonix Pharmaceuticals Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
BioMedNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Q2 Revenue of $13.5 Million as TONMYA Sales Reach $11 Million
Via Investor Brand Network
NetworkNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Q2 Revenue of $13.5 Million as TONMYA Sales Reach $11 Million
Via Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Participate in August, September Investor Conferences
Via Investor Brand Network
TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Receives FDA Feedback for Lyme Disease Prevention Study
Via Investor Brand Network
MissionIRNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Schedules Second-Quarter 2026 Results Call for Aug. 10
Via Investor Brand Network
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Publishes Mpox Research Supporting TNX-801 Vaccine Development
Via Investor Brand Network
BioMedNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Expands TONMYA Medicare Coverage to 145 Million Lives
Via Investor Brand Network
NetworkNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Enrolls First Patient in Phase 2 Depression Trial
Via Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Participate in BTIG Infectious Disease Day 2026
Via Investor Brand Network
MissionIRNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Expands TONMYA Coverage to 52 Million Commercial Lives
Via Investor Brand Network
TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Presents Real-World Data Highlighting Widespread Opioid Use Among Fibromyalgia Patients
Via Investor Brand Network
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Publishes Phase 1 TNX-1500 Data Supporting Advancement into Phase 2
Via Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Presents Real-World Fibromyalgia Burden Data at ISPOR 2026
Via Investor Brand Network
TechMediaBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present Fibromyalgia Real-World Data at ISPOR 2026
Via Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Participate in Two May Investor Conferences
Via Investor Brand Network
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Q1 2026 Results, Highlights TONMYA Commercial Growth and Pipeline Progress
Via Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Secures GPO Agreement Covering 35 Million Lives for TONMYA
Via Investor Brand Network

Frequently Asked Questions

Is Tonix Pharmaceuticals Holding Corp. - Common Stock publicly traded?
Yes, Tonix Pharmaceuticals Holding Corp. - Common Stock is publicly traded.
What exchange does Tonix Pharmaceuticals Holding Corp. - Common Stock trade on?
Tonix Pharmaceuticals Holding Corp. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Tonix Pharmaceuticals Holding Corp. - Common Stock?
The ticker symbol for Tonix Pharmaceuticals Holding Corp. - Common Stock is TNXP on the Nasdaq Stock Market
What is the current price of Tonix Pharmaceuticals Holding Corp. - Common Stock?
The current price of Tonix Pharmaceuticals Holding Corp. - Common Stock is 9.230
When was Tonix Pharmaceuticals Holding Corp. - Common Stock last traded?
The last trade of Tonix Pharmaceuticals Holding Corp. - Common Stock was at 10/01/26 04:00 PM ET
What is the market capitalization of Tonix Pharmaceuticals Holding Corp. - Common Stock?
The market capitalization of Tonix Pharmaceuticals Holding Corp. - Common Stock is 108.70M
How many shares of Tonix Pharmaceuticals Holding Corp. - Common Stock are outstanding?
Tonix Pharmaceuticals Holding Corp. - Common Stock has 109M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.